A radioimmunoassay that sandwiches human interleukin-2 between radiolabeled monoclonal antibody and the receptor on a hematopoietic cell line.
Two monoclonal antibodies were raised against human interleukin-2 (IL-2) produced by E. coli harboring recombinant complemental DNA. Both antibodies did not neutralize its activity, nor did they inhibit the binding of IL-2 to the receptor on target cells. Taking advantage of the ability of monoclonal antibodies to detect IL-2 that had bound to the receptor, a radioimmunoassay was developed that sandwiched IL-2 between the radiolabeled monoclonal antibody and the receptor on a hematopoietic cell line infected with human T cell leukemia virus Type I. The assay had the advantage of detecting only IL-2 with the ability to bind to the receptor, and displayed a linear dose-response relationship over concentrations ranging from 5 to 100 ng/ml.
D000911:Antibodies, Monoclonal / Q000276:immunology*; D002460:Cell Line; D017977:Deltaretrovirus; D004306:Dose-Response Relationship, Immunologic; D006412:Hematopoietic Stem Cells / Q000032:analysis*; D006801:Humans; D007376:Interleukin-2 / Q000032:analysis* / Q000276:immunology; D007938:Leukemia / Q000276:immunology; D009182:Mycosis Fungoides / Q000032:analysis; D011863:Radioimmunoassay / Q000379:methods*; D011971:Receptors, Immunologic / Q000276:immunology*; D015375:Receptors, Interleukin-2
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2